UBS AM
FATE icon

UBS AM’s Fate Therapeutics FATE Stock Holding History

UBS AM’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.2K Hold
815
– – ﹤0.01% 3525
2026
Q1 		$978 Buy
+815
New +$992 ﹤0.01% 3679
2024
Q4 		– Sell
-142,131
Closed -$497K – 2689
2024
Q3 		$497K Sell
142,131
-46,329
-25% -$180K ﹤0.01% 2648
2024
Q2 		$618K Buy
+188,460
New +$825K ﹤0.01% 2568
2023
Q4 		– Sell
-35,408
Closed -$75.1K – 2564
2023
Q3 		$75.1K Hold
35,408
– – ﹤0.01% 2573
2023
Q2 		$202K Hold
35,408
– – ﹤0.01% 2568
2023
Q1 		$202K Sell
35,408
-42,743
-55% -$258K ﹤0.01% 2568
2022
Q4 		$789K Sell
78,151
-332,742
-81% -$6.25M ﹤0.01% 1970
2022
Q3 		$9.21M Sell
410,893
-103,204
-20% -$2.98M 0.01% 988
2022
Q2 		$12.7M Buy
514,097
+70,047
+16% +$1.93M 0.01% 872
2022
Q1 		$17.2M Buy
444,050
+16,707
+4% +$647K 0.01% 880
2021
Q4 		$25M Buy
427,343
+67,934
+19% +$3.85M 0.01% 845
2021
Q3 		$21.3M Buy
359,409
+15,842
+5% +$1.24M 0.01% 846
2021
Q2 		$29.8M Buy
343,567
+43,974
+15% +$3.54M 0.01% 781
2021
Q1 		$24.7M Sell
299,593
-110,832
-27% -$10.6M 0.01% 808
2020
Q4 		$37.3M Sell
410,425
-157,111
-28% -$9.76M 0.02% 682
2020
Q3 		$22.7M Buy
567,536
+10,462
+2% +$365K 0.01% 732
2020
Q2 		$19.1M Buy
557,074
+190,517
+52% +$5.68M 0.01% 754
2020
Q1 		$8.14M Sell
366,557
-184,939
-34% -$4.68M 0.01% 913
2019
Q4 		$10.8M Buy
551,496
+220
+0% +$3.49K 0.01% 918
2019
Q3 		$8.56M Buy
551,276
+12,345
+2% +$237K 0.01% 1007
2019
Q2 		$10.9M Buy
538,931
+7,230
+1% +$130K 0.01% 928
2019
Q1 		$9.34M Buy
531,701
+18,197
+4% +$287K 0.01% 951
2018
Q4 		$6.59M Buy
513,504
+447,726
+681% +$6.24M 0.01% 988
2018
Q3 		$1.07M Buy
+65,778
New +$778K ﹤0.01% 1784

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UBS AM's FATE Position: Q2 2026 in Review

UBS AM held its Fate Therapeutics (FATE) position steady in Q2 2026 at 815 shares worth $2.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3525.

UBS AM first reported a position in FATE in Q3 2018 and has held it in 25 quarters since. The position peaked at $37.3M in Q4 2020. 155 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • UBS AM held 815 shares of Fate Therapeutics worth $2.2K as of Q2 2026.
  • UBS AM left its Fate Therapeutics share count unchanged in Q2 2026.
  • Fate Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3525 holding.
  • UBS AM first reported a position in Fate Therapeutics in Q3 2018 and has held it in 25 quarters since.
  • UBS AM's Fate Therapeutics position peaked at $37.3M in Q4 2020.
  • 155 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.